NMRA NEUMORA THERAPEUTICS INC

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update.

A live webcast of the event will be available on the events and presentations section of the Company’s website at . A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call and are advised to do so at least 10 minutes prior to joining the call.

About Neumora

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

Neumora Contact:

Helen Rubinstein

617-402-5700



EN
28/04/2025

Underlying

NMRANEUMORA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUMORA THERAPEUTICS INC

 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics to Report First Quarter 2025 Financial Results on...

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events a...

April 28, 2025 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Be...

NEW YORK--(BUSINESS WIRE)-- , a leading national securities law firm, is investigating potential claims against Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) and reminds investors of the April 7. 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See . As detailed below, the co...

March 24, 2025 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics to Present at Leerink Global Healthcare Conferenc...

Neumora Therapeutics to Present at Leerink Global Healthcare Conference WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will present at the Leerink Global Healthcare Conference being held in Miami, FL on Tuesday, March 11, 2025 at 10:00 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of the Company’s website at . A ...

March 4, 2025 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financi...

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in Alzheimer’s disease agitation expected by the end of 2025 Expect to progress next M4 positive allosteric modulator (PAM) program into the clinic by mid-2025 Strong financial position with $307.6 million in cash, cash equivalents and marketable securities expected...

March 3, 2025 1 EN
 PRESS RELEASE
Free
NMRA NEUMORA THERAPE...

Neumora Therapeutics Announces Leadership Transition

Neumora Therapeutics Announces Leadership Transition Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael Milligan to serve as chief financial officer Neumora to host conference call on March 3, 2025 to report its fourth quarter and full year 2024 financial results and provide a business update WATERTOWN, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a c...

February 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch